26th Mar 2026 18:30
Notice of Extraordinary General Meeting of Newbury Pharmaceuticals AB
Tid: 15 april 2026 klockan 10.00.Plats: Medicon Village, Scheeletorget 1, Lund.
Time: 15 April 2026 at 10:00 am.Place: Medicon Village, Scheeletorget 1, Lund.
R¤tt att delta p¥ st¤mman:Right to participate:R¤tt att delta i bolagsst¤mman har aktie¤gare som dels ¤r inf¶rd i eget namn i den av Euroclear Sweden AB f¶rda aktieboken tisdagen den 7 april 2026, dels anm¤ler sin avsikt att delta i st¤mman senast torsdagen den 9 april 2026.
Shareholders who wish to participate in the Extraordinary General Meeting shall be recorded in their own name in the printout of the share register made by Euroclear Sweden AB on Tuesday 7 April 2026 and shall notify the company of their intention to attend no later than Thursday 9 April 2026.
F¶rvaltarregistrerade aktier:Nominee registered shares:Aktie¤gare som l¥tit f¶rvaltarregistrera sina aktier m¥ste, f¶r att ha r¤tt att delta i bolagsst¤mman, inregistrera aktierna i eget namn i den av Euroclear Sweden AB f¶rda aktieboken. S¥dan omregistrering m¥ste vara verkst¤lld innan tisdagen den 7 april 2026. Aktie¤gare m¥ste i god tid f¶re denna dag meddela sin beg¤ran h¤rom till f¶rvaltaren.
Shareholders whose shares are registered in the name of nominees must â€" in addition to their notification to attend the meeting â€" re-register such shares in their own name at Euroclear. Such registration must be effected no later than Tuesday 7 April 2026. Shareholders must inform their nominees and request re-registration well in advance of this date.
Anm¤lan:Notification:Anm¤l senast torsdagen den 9 april 2026 per e-post till [email protected]. Vid anm¤lan uppges namn, personnummer/organisationsnummer, adress, telefonnummer och antal aktier. Aktie¤gare som f¶retr¤ds genom ombud b¶r ¶vers¤nda skriftlig och daterad fullmakt till bolaget samtidigt med anm¤lan. Fullmakts giltighet f¥r anges till l¤ngst fem ¥r fr¥n utf¤rdandet. Den som f¶retr¤der juridisk person ska kunna visa registreringsbevis eller motsvarande beh¶righetshandling som anger beh¶rig firmatecknare. Fullmakt (original), registreringsbevis eller motsvarande beh¶righetshandlingar, som inte ¶vers¤nts till bolaget i samband med anm¤lan, ska medtas till st¤mman. Fullmaktsformul¤r finns tillg¤ngligt p¥ bolagets hemsida (www.newburypharma.com).
Notification of attendance no later than Thursday 9 April 2026 by e-mail to [email protected]. Please state name, personal identity number/corporate identity number, address, telephone number and number of shares. Shareholders represented by proxy should send a written and dated proxy together with the notification of attendance. The validity of the proxy may be stated to be no more than five years from the date of issuance. A proxy form for this purpose is provided at www.newburypharma.com. If requested, the proxy shall be presented in original. Representatives of a legal entity shall present a certificate of registration or a corresponding document of qualification showing the person (s) authorized to sign for the legal entity.
Dagordning:Agenda:
1. St¤mmans ¶ppnande och val av ordf¶rande f¶r st¤mman1. Opening of the general meeting and election of chairman of the general meeting
2. Uppr¤ttande och godk¤nnande av r¶stl¤ngd2. Preparation and approval of the voting list
3. Val av en eller flera justerare3. Election of one or two persons to verify the minutes
4. Pr¶vning av om st¤mman blivit beh¶rigen sammankallad4. Determination as to whether the meeting has been duly convened
5. Godk¤nnande av dagordningen5. Approval of the agenda
6. Godk¤nnande av tredje till¤gget till l¥neavtal med n¤rst¥ende part6. Approval of Third Amendment to Loan Agreement â€" related party transaction
7. Val av ny revisor7. Election of new auditor
8. St¤mman avslutas8. Closing of the general meeting
Punkt 1 / Item 1Styrelsen f¶resl¥r att Christoffer Tell v¤ljs till ordf¶rande vid st¤mman.
The board proposes that Christoffer Tell be elected as chairman of the general meeting.
Punkt 6 / Item 6Styrelsen f¶resl¥r att st¤mman godk¤nner det tredje till¤gget daterat 26 mars 2026 till l¥neavtalet mellan Newbury Pharmaceuticals AB och AB Sl¤dens Pensionsstiftelse nr 3, ursprungligen ing¥nget den 18 september 2023. Till¤gget inneb¤r: (i) f¶rl¤ngning av l¥nets l¶ptid med 12 m¥nader till den 30 juni 2027, (ii) ut¶kning av l¥nebeloppet med 15 MSEK till totalt 30 MSEK, utbetalning inom 30 dagar fr¥n signering, samt (iii) en ny klausul som kr¤ver l¥ngivarens skriftliga godk¤nnande inf¶r eventuella factoringl¶sningar. -vriga villkor, inklusive r¤ntan om 11 procent per ¥r, kvarst¥r of¶r¤ndrade.L¥ngivaren, AB Sl¤dens Pensionsstiftelse nr 3, f¶retr¤ds av Johan Orvelin, som ¤ven ¤r styrelseledamot i Newbury Pharmaceuticals AB. Transaktionen utg¶r d¤rf¶r en n¤rst¥ende transaktion. De oberoende styrelseledam¶terna har bed¶mt att transaktionen genomf¶rs p¥ marknadsm¤ssiga villkor och ¤r i bolagets och aktie¤garnas intresse. Bolagets Certified Adviser, V¤stra Hamnen Corporate Finance, har informerats.
The board proposes that the meeting approves the Third Amendment dated 26 March 2026 to the Loan Agreement between Newbury Pharmaceuticals AB and AB Sl¤dens Pensionsstiftelse nr 3, originally entered into on 18 September 2023. The amendment comprises: (i) a 12-month extension of the loan maturity to 30 June 2027, (ii) an increase of the loan principal by SEK 15 million to a total of SEK 30 million, disbursed within 30 days of signing, and (iii) a new clause requiring the Lender’s prior written consent for any factoring or receivables financing arrangement. All other terms, including the interest rate of 11% per annum, remain unchanged.The lender, AB Sl¤dens Pensionsstiftelse nr 3, is represented by Johan Orvelin, who is also a member of the Board of Directors of Newbury Pharmaceuticals AB. The transaction is therefore treated as a related party transaction. The independent board members have assessed that the transaction is conducted on arm’s length terms and is in the best interests of the company and its shareholders.
Punkt 7 / Item 7Styrelsen f¶resl¥r att st¤mman beslutar att entlediga Martin Henriksson, EY, som bolagets revisor samt att v¤lja Jesper Ahlkvist, auktoriserad revisor och partner p¥ Forvis Mazars AB, till ny revisor f¶r tiden intill slutet av n¤sta ordinarie bolagsst¤mma.Som information till aktie¤garna kan n¤mnas att bolaget har genomf¶rt en upphandling av revisorstj¤nster.
The board proposes to discharge Martin Henriksson, EY, as the company’s auditor and to elect Jesper Ahlkvist, authorised public accountant and partner at Forvis Mazars AB, as new auditor until the end of the next annual general meeting.For the information of the shareholders, it may be noted that the company has conducted a procurement process for audit services.
Fullst¤ndiga beslutsf¶rslag och ¶vriga handlingar h¥lls tillg¤ngliga p¥ bolagets webbplats newburypharma.com/investors/ senast tv¥ veckor f¶re st¤mman.
Complete proposals and other documents will be available on the company’s website newburypharma.com/investors/ no later than two weeks before the meeting.
Styrelsen f¶r Newbury Pharmaceuticals AB / The board of Newbury Pharmaceuticals ABorg. nr. 559274-2463 /
For more information, contact:
Karl Karlsson, CEO[email protected]Mobile: +46 46 12 11 20
www.newburypharma.com
About Newbury Pharmaceuticals
Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and an extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.
V¤stra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at [email protected] or +46 (0) 40 200 250.
Attachments
Kallelse till extra bolagsst¤mma i Newbury Pharmaceuticals AB